Profile: Bellerophon Therapeutics Inc (BLPH.OQ)
20 May 2019
Bellerophon Therapeutics, Inc., incorporated on October 17, 2013, is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. The Company also develops Bioabsorbable Cardiac Matrix (BCM).
The Company's INOpulse program is an extension of the technology used in hospitals to deliver continuous-flow inhaled nitric oxide. Its INOpulse program is developed for the therapeutic delivery of inhaled nitric oxide. The Company has designed its INOpulse device, which is the means by which inhaled nitric oxide is delivered to the patient, to be portable, which enables use by ambulatory patients on a daily basis inside or outside their homes. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment.
INOpulse is designed to automatically adjust nitric oxide delivery based on a patient's breathing pattern to deliver a constant and appropriate dose of the inhaled nitric oxide over time, independent of the patient's activity level. In its INOpulse clinical trials, the Company used the first generation INOpulse device, which the Company refers to as the INOpulse DS device. In addition, the Company has developed a triple-lumen nasal cannula, which forms part of the Mark2 and enables dosing of nitric oxide and minimizes infiltration of oxygen, which can react with nitric oxide to form nitrogen dioxide. Its triple-lumen nasal cannula consists of a thin, plastic tube that is divided into three channels from end-to-end, including at the prongs that are placed in the patient's nostrils, with one channel delivering inhaled nitric oxide, a second for breath detection and a third available for oxygen delivery. INOpulse is designed to be compatible with many long-term oxygen therapy (LTOT) systems via nasal cannula delivery.
The Company is developing INOpulse for the treatment of PAH to address medical needs in an orphan disease. It completed a randomized, placebo-controlled, double-blind Phase II clinical trial of INOpulse for PAH. The data from this trial showed trends toward lower pulmonary vascular resistance in both active arms compared to placebo and a slight trend toward increased six-minute walk distance in the higher dose group. The Company is also developing INOpulse for the treatment of PH-COPD.
The Company's second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company's BCM is in PRESERVATION I clinical trial.
The Company competes with GlaxoSmithKline, United Therapeutics Corporation, Actelion Pharmaceuticals US, Inc., Pfizer Inc., Gilead Sciences, Inc., Bayer HealthCare Pharmaceuticals Inc., GeNO LLC, Mast Therapeutics., Insmed, Inc. and SteadyMed Therapeutics, Inc.
Bellerophon Therapeutics Inc
184 Liberty Corner Rd Ste 302
WARREN NJ 07059-6796